arrow-circle-full-right arrow-circle-full-up arrow-circle-up arrow-down arrow-right calendar calendar-done facebook flickr home linkedin login pin reload search share signin star twitter video video youtube nav star-plus info signout double-arrow arrow-up checked
Healthcare & Life Sciences

FT Pharma Pricing and Value Summit 2018

Navigating the Market Access Landscape

New York |
Speakers include:
Alex Azar

Alex Azar

United States

Seema Verma

Seema Verma

Centers for Medicare & Medicaid Services

Leonard Schleifer

Leonard Schleifer



The American healthcare landscape is full of uncertainty, especially when it comes to drug pricing and market access. Pressures and priorities vary among stakeholders but whether it’s pharma, payer, PBM, provider or patient, everyone is looking for VALUE

The FT Pharma Pricing and Value Summit will discuss the future of pharmaceutical pricing and market access in an evolving healthcare environment. Topics on agenda include the politics of drug pricing, the rise of real-world evidence, the role of pharmacy benefit managers and what value means to different stakeholders.

fallback Add to my Calendar 09/13/2018 08:00:0009/13/2018 16:30:00trueFT Pharma Pricing and Value Summit 2018The American healthcare landscape is full of uncertainty, especially when it comes to drug pricing and market access. Pressures and priorities vary among stakeholders but whether it’s pharma, payer, PBM, provider or patient, everyone is looking for VALUE. The FT Pharma Pricing and Value Summit will discuss the future of pharmaceutical pricing and market access in an evolving healthcare environment. Topics on agenda include the politics of drug pricing, the rise of real-world evidence, the role of pharmacy benefit managers and what value means to different stakeholders.FT-Pharma-Pricing-and-Value-Summit-2018471733c6ef2ccb59930f856ef3e642ddMM/DD/YYYY

2018 Photos

View the 2018 event photos here.



Keynote (1)

Alex Azar

Alex Azar

Secretary of Health and Human Services
United States

Alex M. Azar II was sworn in as the Secretary of Health and Human Services on Jan. 29, 2018. Azar has spent his career working in both the public and private sectors, as an attorney and in senior leadership roles focused on advancing healthcare reform, research and innovation.

From 2001 to 2007, Azar served at the U.S. Department of Health and Human Services – first as its General Counsel (2001–2005) and then as Deputy Secretary. During his time as Deputy Secretary, Azar was involved in improving the department’s operations; advancing its emergency preparedness and response capabilities as well as its global health affairs activities; and helping oversee the rollout of the Medicare Part D prescription drug program.

In 2007, Azar rejoined the private sector as senior vice president for corporate affairs and communications at Eli Lilly and Co. From 2012 to 2017, he served as president of Lilly USA LLC, the company’s largest affiliate.

Azar clerked for U.S. Supreme Court Justice Antonin Scalia prior to practicing law for several years.

Azar graduated summa cum laude with a bachelor’s degree in economics and government from Dartmouth College and earned his law degree from Yale University.

For the past 10 years, Azar has lived in Indiana with his wife and their two children.

Speakers (18)

Seema Verma

Seema Verma

Centers for Medicare & Medicaid Services

Seema Verma currently serves as Administrator of the Centers for Medicare & Medicaid Services (CMS), and she is only the 15th person ever confirmed to the post. She was nominated by President Trump on November 29, 2016 – the seventh nomination by the President-elect – and confirmed by the U.S. Senate on March 13, 2017. As Administrator, Ms Verma oversees a $1 trillion budget, 26% of the total federal budget, and administers healthcare programs for more than 130 million Americans every day.

A nationally recognized leader in health policy and operational design, she has guided healthcare policy in the public and private sector, working with states to build flexibility into their Medicaid programs to help them meet the diverse needs of their unique populations. 

Administrator Verma is a graduate of the University of Maryland, and holds a Master’s degree in Public Health with a concentration in health policy and management from Johns Hopkins University.

Her editorial commentaries have appeared in the Wall Street Journal, Washington Post and Health Affairs, and she also previously served as Vice President of Planning for the Health & Hospital Corporation of Marion County, Indiana and most recently before heading CMS was President and CEO of SVC, Inc.

Leonard Schleifer

Leonard Schleifer

President and CEO

Leonard Schleifer is the longest serving CEO of a major US biotechnology company. He founded Regeneron Pharmaceuticals in 1988, with Eric Shooter, a leading researcher in the area of nerve growth factors, and Alfred G. Gilman, who received the 1994 Nobel Prize in Medicine for Physiology. Prior to starting Regeneron, he was Assistant Professor at the Cornell University Medical College in the Departments of Neurology and Neurobiology. Dr Schleifer, together with George Yancopoulos, Chief Scientific Officer and a Founding Scientist of the company, have grown Regeneron over 25 years from a tiny start-up to an over $40 billion market cap company with four FDA-approved drugs - PRALUENT ® (alirocumab) Injection, EYLEA ® (aflibercept) Injection, ZALTRAP ® (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST ® (rilonacept) Injection. Under Dr Schleifer’s leadership, the company has established key business collaborations and developed industry- leading technologies for drug discovery and development, resulting in a robust pipeline of monoclonal antibody candidates in areas of high unmet need. In 2011, Dr Schleifer was selected as New York Region Entrepreneur of the Year in Healthcare by Ernst & Young and was appointed by New York Governor Andrew Cuomo Co-Chair of the Mid-Hudson Region Economic Development Council.
Dr Schleifer graduated Phi Beta Kappa and summa cum laude from Cornell University and was awarded his MD and PhD in Pharmacology from the University of Virginia. He is Certified in Neurology by the American Board of Psychiatry and Neurology.

Susan Shiff

Susan Shiff

Senior Vice President, Center for Observational and Real-World Evidence

Susan Shiff joined Merck in 2014 as Senior Vice President and head of the CORE organization. CORE links together epidemiologists, health economists, access and reimbursement scientists, health services researchers and others involved in health policy research with the goal of leading global strategic value evidence generation and access strategy development to optimize reimbursement and patient outcomes across Merck’s portfolio.

Prior to joining Merck, Dr Shiff was the Global Vice President, Health Economics Research and Evidence Based Medicine at Teva. Prior to Teva, she spent seven years at Pfizer, including several years as Vice President in the areas of outcomes research, epidemiology, health economics, and access and pricing. She has also led the global risk management group and US HEOR group at Roche and spent four years at the US Centers for Disease Control and Prevention (CDC).

Dr Shiff received her PhD degree from UCLA, and an MBA degree from Cornell University. She currently serves on the Institute for Clinical and Economic Review (ICER), Advisory Board and Methods Sub-Committee; Health Technology Assessment International (HTAi), Policy Advisory Board; the Innovation and Value Initiative (IVI), Panel of Health Advisors, the Academy of Managed Care Pharmacy (AMCP) Foundation Board, and the New Jersey Symphony Orchestra, Board of Trustees, Education, and Development Committees. She is also a Non-Executive Director of Synthace Ltd. In 2016, Dr Shiff was named one of the top 15 women in Biopharma by FiercePharma.

Robert E. Andrews

Robert E. Andrews

Health Transformation Alliance

Robert E. Andrews currently serves as Chief Executive Officer of the Health Transformation Alliance (HTA). As CEO of the HTA, Mr Andrews oversees the strategic direction of 40+ major corporations who have come together in an alliance to do one thing: fix our broken healthcare system. Formed by four founding members in September 2015, the HTA has grown to include more than forty of our nation’s leading employers, who collectively are responsible for more than seven million employees, dependents and retirees and an annual health care spend of $26 billion. Through Mr Andrews’ leadership, the HTA has launched value-driven solutions specifically designed to improve patient care and economic value through world class data & analytics, path-breaking pharmaceutical solutions, high quality medical networks and robust consumer engagement initiatives.

Mr Andrews previously led the Government Affairs practice at Dilworth Paxson law firm for two years before joining the HTA.

Prior to private practice, Mr Andrews served as a Member of the United States House of Representatives for nearly 24 years. Upon his departure from the Congress, President Barack Obama praised Andrews’ service as “an original author of the Affordable Care Act...and a vital partner in its passage and implementation,” and cited his “tenacity and skill” in representing the people of New Jersey.

Alan Balch

Alan Balch

Patient Advocate Foundation

Alan Balch is the Chief Executive Officer of Patient Advocate Foundation and National Patient Advocate Foundation.

Dr Balch has nearly fifteen years of executive leadership in the non-profit sector with an emphasis on consensus-building and collaboration. He has led numerous federal advocacy efforts on a range of issues both at the legislative and regulatory level over the years. He became the CEO of both PAF and NPAF in 2013. From 2006 to 2013, he served as the Vice President of the Preventive Health Partnership – a national health promotion collaboration between the American Cancer Society, American Diabetes Association, and American Heart Association. Prior to his work with the Preventive Health Partnership, Dr Balch was the Executive Director of Friends of Cancer Research.

Dr Balch has served on the Executive Board of the Patient Advocate Foundation and National Patient Advocate Foundation since 2007. Dr Balch also serves on numerous advisory boards and committees.

Dr Balch earned his PhD in Environmental Studies with a concentration in Political Economy in 2003 from the University of California, Santa Cruz; his Master’s degree in Environmental Sciences in 1997 from the University of Texas in San Antonio; his Bachelor’s degree (cum laude) in Biology in 1994 from Trinity University in San Antonio.

Kristin Bass

Kristin Bass

Senior Vice President, Policy and Federal Affairs
Pharmaceutical Care Management Association

Kristin Bass is the Senior Vice President of Policy and Federal Affairs at the Pharmaceutical Care Management Association. In this role, she leads PCMA’s strategic development of the industry’s legislative policies. Ms Bass joined PCMA from the Senate Finance Committee staff, where she served as Health Policy Advisor to Ranking Minority Member Chuck Grassley (R-IA), with responsibility for private plan options in Medicare and commercial insurance issues.

Previously, Ms Bass was the Senior Vice President for Policy at the Healthcare Leadership Council, where she led efforts on health IT, privacy, and quality improvement. Prior to that, she headed WellPoint, Inc.‘s Federal Affairs office and before that, the federal lobbying team at the American Association of Health Plans (now AHIP). She holds a BA and an MBA from Yale University.

Marc Boutin

Marc Boutin

National Health Council

Marc Boutin is the Chief Executive Officer of the National Health Council, the only organization that brings together all segments of the health community to provide a united voice for the more than 133 million people with chronic diseases and disabilities and their family caregivers.

Made up of more than 100 diverse national health-related organizations and businesses, the NHC's core membership includes the nation’s leading patient advocacy organizations, which control its governance and policy-making process. Other members include professional and membership associations, nonprofit organizations with an interest in health, and representatives from the pharmaceutical, generic drug, health insurance, device, biotechnology, and communication industries.

Mr Boutin has been a leading voice for greater patient involvement at every stage of the continuum, starting with the development of new drugs, to regulatory oversight of health care delivery, to shared decision-making at the point of care. Under his leadership, the NHC has convened a broad range of stakeholders to create and effectively implement pragmatic strategies and public policy that address diverse issues, such as enhancing patient engagement, advancing the development of new treatments, and developing a better health delivery system to meet the needs of people with chronic conditions.

Mr Boutin has a long history of Board and Committee service. Currently he serves as a member of the AdaptSmart International Advisory Board, NEST Governing Committee and Subcommittee Charter, Patient-Centered Research Foundation, Patient Focused Medicines Development (PFMD), MDIC Patient-Centered Benefit-Risk Steering Committee/Patient Engagement Steering Committee, and PhRMA Stakeholder Advisory Committee

Mr Boutin is a former civil rights litigator. He received his bachelor of economics degree in international politics/law from the University College of Wales, Aberystwyth, United Kingdom and his JD from Suffolk University Law School in Boston, Massachusetts.

Don Creighton

Don Creighton

Managing Director
Huron Life Sciences Practice

Don Creighton has more than 20 of years of experience in industry, consulting and scientific research with expert knowledge of payer systems and pricing & market access strategy.

Mr Creighton has worked across a broad array of therapy areas and geographies with projects spanning the development continuum including US and global pricing and contracting strategies for Phase III / launch, Phase II assessments to inform Phase III ’go/no go’ and protocol development as well as early phase and BD/in-licensing evaluations for pipeline prioritization and asset acquisition decisions.

Prior to joining Huron, Mr Creighton worked in the Commercialization & Outcomes Division of ICON Clinical Research for six years, leading the Global Pricing & Market Access Practice since 2016. He also serves on the In Vivo Advisory Editorial Board.

Previously, Mr Creighton worked at Pfizer for nine years serving as Global Market Access Lead in the Specialty Care and Oncology Business Units, where he launched the first NSCLC therapy with a companion diagnostic, XALKORI. He started his career at Cambridge Pharma Consultancy (now part of IQVIA/ IMS Health) specializing in pricing and reimbursement strategy.

Donna Cryer

Donna Cryer

President and CEO
Global Liver Institute

Donna R. Cryer, JD, has channeled her personal experience as an IBD and liver transplant patient into professional advocacy as president and chief executive officer of the Global Liver Institute, the innovation and collaboration platform for liver health worldwide. An attorney and award-winning patient advocate, she is an entrepreneurial business executive with expertise in digital health, precision medicine, drug development and health policy.

For more than a decade Mrs Cryer led CryerHealth, a healthcare consulting firm she founded, providing strategic counsel to top biopharmaceutical companies, patient advocacy organizations, and emerging technology firms on patient engagement in health information technology, drug discovery and clinical decision making. She is a frequent speaker on the topic of patient-centeredness and patient engagement in healthcare transformation.

Mrs Cryer serves on the Executive Committees of the People-Centered Research Foundation and the Clinical Trial Transformation Initiative, and also as a member of the Board Trustees of Sibley Memorial Hospital/Johns Hopkins Medicine. She is also on the Executive Advisory Board for Tivity Health (Nasdaq TVTY), a company focused on fitness and health improvement programs for mature consumers and is serving her second term as a patient representative to the US Food and Drug Administration.

Mrs Cryer has been named one of the Top Blacks in Healthcare by the Milken Institute at GW

School of Public Health and, one of the Top 10 Patients Who Make An Impact by Health 2.0 and one of PharmaVoice’s 100 Most Inspiring People.

Mrs Cryer received an undergraduate degree from Harvard/Radcliffe Colleges and a Juris Doctorate from the Georgetown University Law Center.

Sarah Emond

Sarah Emond

Executive Vice President and Chief Operating Officer
Institute for Clinical and Economic Review (ICER)

Sarah Emond leads the strategic planning and operations of the Institute for Clinical and Economic Review (ICER), a leading non-profit health policy research organisation, as Executive Vice President and Chief Operating Officer. In that role, she is responsible for overseeing ICER’s public programs, communications, operations, and finances.
Prior to joining ICER, Ms Emond spent time as a communications consultant, with six years in the corporate communications and investor relations department at a commercial-stage biopharmaceutical company, and several years with a healthcare communications firm. She began her healthcare career in clinical research at Beth Israel Deaconess Medical Center in Boston.
A graduate of the Heller School for Social Policy and Management at Brandeis University, Ms Emond holds a Master of Public Policy degree with a concentration in health policy. She also received a Bachelor’s degree in Biological Sciences from Smith College.

Leanne Gassaway

Leanne Gassaway

Senior Vice President, State Affairs
America’s Health Insurance Plans

Leanne Gassaway is a passionate health care advocate and is the Senior Vice President for State Affairs for America’s Health Insurance Plans. AHIP is the national trade association representing the health Insurance industry. AHIP’s members provide health and supplemental benefits through employer-sponsored coverage, the individual insurance market, and public programs such as Medicare and Medicaid.

Overseeing state affairs for AHIP, Ms Gassaway is responsible for assisting in legislative, regulatory and policy advocacy efforts in the states. This includes activities at various political and regulatory organizations, such as the National Association of Insurance Commissioners (NAIC), National Governors Association (NGA) and the National Association of Attorneys General (NAAG). She also is focused on federal and state driven efforts regarding health care and insurance including the Patient Protection and Affordable Care Act (ACA).  
Prior to coming to AHIP, Ms Gassaway had an active tenure working in government affairs and project management. She began her career in 1994 at PacifiCare Health Systems, now a UnitedHealthcare company. At PacifiCare, she was the Director of Regulatory Advocacy for all business lines. She also worked for CIGNA Corporation as the Western Region Government Affairs Director. In these positions, she was responsible for government relations activity affecting medical, dental, vision, pharmacy and behavioral health issues. She participated in education and policy collaborations with key health care stakeholders on a variety of matters. She also served as Vice President of Legal and Regulatory Affairs for the California Association of Health Plans. In this capacity, she oversaw legal and regulatory issues for 40 full service health plans and Medi-Cal managed care plans in California. She was responsible for managing the relationships with the Department of Managed Health Care, Office of Patient Advocate, Department of Health Services, Major Risk Medical Insurance Board, Department of Insurance, and the Centers of Medicare & Medicaid Services.
Ms Gassaway has a Master’s Degree in Health Care Administration from California State University, Long Beach focusing on public policy and health care law. She received a Bachelor’s Degree in Urban and Regional Planning from California State Polytechnic University, Pomona.

Christoph Glaetzer

Christoph Glaetzer

Vice President, Global Market Access

Christoph Glaetzer has more than 20 years’ global experience in the development and implementation of pharmaceutical market access and commercialization strategies. He has worked and lived in Europe, North America and Asia and is currently Vice President, Global Market Access at Janssen covering Health Economics, Pricing, Patient Reported Outcomes (PRO) and Real-World Evidence (RWE). Previous roles at Jannsen include leading the regional Commercial and Access Strategy Organization in Asia-Pacific as well as being a representative at various international forums and initiatives (e.g. PhRMA, EFPIA, GHC, ISPOR, HTAi)

Mr Glaetzer is a champion of new access and pricing concepts to improve health outcomes globally. He is an International thought leader and speaker on commercial strategies, health care policy and pharmaceutical market access aspects.

Clive Meanwell

Clive Meanwell

The Medicines Company

Clive Meanwell is the Chief Executive Officer of The Medicines Company, a New Jersey company which he founded in 1997 while a Managing Partner and Senior Managing Director at MPM Capital in Cambridge, Massachusetts. He is also Vice Chairman of BB Biotech and has been a director of the listed, Swiss corporation which invests in the field of biotechnology since 2003.

Previously, Dr Meanwell was Senior Vice President of Roche Life Sciences, Palo Alto and before that held a series of leadership positions in product development, regulatory affairs and marketing at Roche, mostly based in Switzerland. Earlier in his career he was a member of the Amgen-Roche team that developed and launched Neupogen®.

Before joining the biopharmaceutical industry, Dr Meanwell trained in medicine and then undertook a research fellowship in medical oncology at the University of Birmingham, and the Queen Elizabeth Medical Center, in the United Kingdom.

Jeff Myers

Jeff Myers

President and CEO
Medicaid Health Plans of America

Jeff Myers is the President and CEO of Medicaid Health Plans of America (MHPA), the leading trade association for Medicaid managed care organizations. He serves as the spokesperson for the managed Medicaid industry before Congress, the executive branch, states, and the media, demonstrating the value of Medicaid managed care and leading advocacy efforts for industry policy priorities. Prior to MHPA, Mr Myers was Senior Vice President of Policy and Government Relations at the American Health Care Association, represented the pharmaceutical companies Cephalon, Biogen Idec, Pharmacia, and Hoffman-LaRoche before the legislative and executive branches, and served as US Representative Fred Upton’s Legislative Director and Health Staff for the Energy and Commerce Health Subcommittee. He also worked for US. Representative Alex McMillan where he led Health Staff during consideration of the Health Security Act. Mr Myers received his MBA from Duke’s Fuqua School of Business and his Bachelor’s degree from Rhodes College.

Mark Nagy

Mark Nagy

Vice President, Global Patient Outcomes and Real World Evidence
Eli Lilly

Mark J. Nagy, Vice President, Global Patient Outcomes and Real World Evidence is responsible for leading Eli Lilly and Company’s global health outcomes research organization, along with overseeing efforts to advance the company’s real world evidence capability. As the son of a physician and a nurse, Mr Nagy has spent his entire life thinking about healthcare.  Since joining Lilly in 1989, he has had numerous positions in US brand, global and payer marketing along with international assignments.

Mr Nagy is currently the chairman of the board of directors for the National Pharmaceutical Council.  He is also the co-chairman of both the leadership and executive councils for Jump IN for Healthy Kids, a non-profit collective, community impact initiative focused on addressing childhood obesity in central Indiana.

Mr Nagy received a BBA degree (Finance) from the University of Notre Dame (1985), and his MBA from Northwestern University (1989). In addition to Lilly, Nagy previously worked for two years in corporate finance at E. F. Hutton in New York. 

Robert Popovian

Robert Popovian

Vice President, US Government Relations

Robert Popovian is Vice President, US Government Relations at Pfizer Inc. He brings more than two decades of experience in numerous facets of biopharmaceutical and health care industry with a strong track record of expertise, innovation and results in Health Care Policy and Economics, Government Relations, Medical Affairs, and Strategic Planning.

Dr Popovian has published and presented extensively on the impact of biopharmaceuticals and health policies on health care costs and clinical outcomes, including authorship in clinical and healthcare delivery journals and published expert source in First Word, Los Angeles Times, USA Today, Managed Healthcare Executive, Pink Sheet and Bloomberg News amongst many others. He also writes a monthly column published in Morning Consult regarding health policy and economic issues relevant to the biopharmaceutical industry. He is a frequent speaker at healthcare policy and medical conferences on topics such as payment and delivery reform, biosimilars, policies that enable biopharmaceutical innovation and health economics. He currently serves as a board member for the Global Healthy Living Foundation.

Dr Popovian completed his Doctorate in Pharmacy and Masters of Science in Pharmaceutical Economics and Policy degrees at the University of Southern California with honors. The degree in Pharmaceutical Economics and Policy was the first one conferred by an accredited university in the US. He has also completed a residency in Pharmacy Practice/Adult Internal Medicine and Infectious Diseases at the Los Angeles County – University of Southern California Hospital where he was the head resident pharmacist (primary area of research: gram negative bacteremia) and a fellowship in Pharmaceutical Economics and Policy at University of Southern California (primary area of research: payment reform). 

Michael  Rea

Michael Rea

Founder and CEO
Rx Savings Solutions

Michael Rea founded Rx Savings Solutions in 2008 after routinely witnessing consumers struggling to pay for their medications. He noticed quickly at that time that consumers were paying much more than they needed to, which was attributable to a lack of information available to them. He set out on his mission to arm consumers with this information and add efficiency and transparency back into the world of pharmacy. Dr Rea has been involved with research surrounding pharmacy transparency for over 10 years. He received his Doctor of Pharmacy degree from Creighton University.

Nathan White

Nathan White

Senior Vice President, Integrated Access and Outcomes Solutions
ICON plc

For more than 16 years, Nathan White has been offering clients advice and solutions on global, US, and European market access and reimbursement challenges. He began his career at Express Scripts, working in leadership, field-based, and internal operational roles in the specialty pharmacy and reimbursement support program divisions. He spent more than five years designing and implementing reimbursement operational solutions at PAREXEL Consulting and Syneos Health, before shifting into global access/HEOR consulting and value communications roles as Director of Market Access at Nucleus Global, Managing Director and Head of Market Access at eMAX Health Systems, and Global Practice Lead at ApotheCom Access Pathways and Outcomes.


Chair (1)

David  Crow

David Crow

Senior US Business Correspondent
Financial Times

David Crow is a Senior US Business Correspondent for the Financial Times, covering telecoms, technology, and pharmaceuticals. He is based in New York. He previously worked on the FT's main news desk in London, where he edited the front page of the print edition. Before joining the FT he was Managing Editor of City AM, the London financial newspaper.

Mr Crow has an MA in English Literature from the University of Glasgow.

Agenda - 13th Sep

  • 8:00am
    Registration and refreshments
  • 9:00am
    Opening remarks

    David Crow, Senior US Business Correspondent, Financial Times

  • 9:05am
    Keynote address

    Alex Azar, United States Secretary of Health and Human Services

  • 9:35am
    Keynote interview

    Leonard Schleifer, President and CEO, Regeneron

    Interviewed by David Crow, Senior US Business Correspondent, Financial Times

  • 10:05am
    Re-evaluating “value” – strategies for success

    Pharma companies need more sophisticated value stewardship if they are to meet the changing expectations of payers and other stakeholders. Hear how leadership roles are evolving, with a reassessment of risk-bearing approaches to value creation; more patient-centric communication practices; and better governance of market access.   

    Don Creighton, Managing Director, Huron Life Sciences Practice

  • 10:25am
    Panel: Pricing pressures and healthcare reform
    • What could fuel pricing pressures on pharma in the coming months?
    • How could healthcare reform change the market access landscape?
    • What can be done to encourage open dialogue and overcome political barriers?
    • What are the prospects for a shift towards single-payer healthcare in the US?

    Donna Cryer, President and CEO, Global Liver Institute

    Jeff Myers, President and CEO, Medicaid Health Plans of America

    Sarah Emond, Executive Vice President and Chief Operating Officer, Institute for Clinical and Economic Review

    Robert Popovian, Vice President, US Government Relations, Pfizer

    Moderated by David Crow, Senior US Business Correspondent, Financial Times

  • 11:10am
    Morning refreshments
  • 11:30am
    Shifting the balance of power in pricing negotiations

    Companies are coming together to strengthen their negotiating position for healthcare coverage. Will this be an effective and sustainable way of reducing drug prices?  

    Robert E. Andrews, CEO, Health Transformation Alliance

  • 12:00pm
    Industry analysis: Payer and manufacturer perspectives on ICER impact

    The short and long-term impact of Institute for Clinical and Economic Review (ICER) assessments on payer and manufacturer decision-making surrounding drug pricing, coverage, access, and reimbursement are still not known. ICON will present results and analysis from a 2018 research study of more than 50 payer and manufacturer organisations and their perceptions of ICER’s impact on both the manufacturer and payer communities.

    Nathan White, Senior Vice President, Integrated Access and Outcomes Solutions, ICON plc

  • 12:20pm
    Panel: The rise of real world evidence
    • What are the prospects for the application and regulation of real world evidence in pricing models?
    • How is real-world evidence changing the way stakeholders interact?
    • How is technology and data linkage evolving to support the use of real world evidence?
    • How can real world evidence be applied in risk-sharing models?

    Clive Meanwell, CEO, The Medicines Company

    Mark Nagy, Vice President, Global Patient Outcomes and Real World Evidence, Eli Lilly

    Susan Shiff, Senior Vice President, Center for Observational and Real-World Evidence, Merck

    Moderated by David Crow, Senior US Business Correspondent, Financial Times

  • 1:05pm
    Networking lunch
  • 2:00pm
    Fireside chat: The evolving role of pharmacy benefit managers

    Gain insights into the role of PBMs in pricing negotiations, the value they can extract for other stakeholders and the pressures they are facing.

    Kristin Bass, Senior Vice President, Policy and Federal Affairs, Pharmaceutical Care Management Association

    Interviewed by David Crow, Senior US Business Correspondent, Financial Times

  • 2:30pm
    A patient perspective: Affordability and sustainability

    While stakeholders blame each other for rising drug prices, people with chronic conditions increasingly can’t afford the medical care they need. How do we address rising health care costs while ensuring meaningful access to high value care?

    Marc Boutin, CEO, National Health Council

  • 3:00pm
    Stakeholder exchange: Bridging the value gap

    Hear representatives of different parts of the pharma pricing value chain exchange points of view and ideas with a focus on finding win-win solutions to the problems they face.     

    • How do different stakeholders express and measure value?
    • How can value for patients be increased in a way that is sustainable?
    • Could new players in the market have an impact on pricing?

    Alan Balch, CEO, Patient Advocate Foundation

    Leanne Gassaway, Senior Vice President, State Affairs, America’s Health Insurance Plans

    Christoph Glaetzer, Vice President, Global Market Access, Janssen

    Michael Rea, Founder and CEO, Rx Savings Solutions

    Moderated by David Crow, Senior US Business Correspondent, Financial Times

  • 3:45pm
    Closing address

    Seema Verma, Administrator, Centers for Medicare & Medicaid Services

  • 4:15pm
    Closing remarks

    David Crow, Senior US Business Correspondent, Financial Times

  • 4:20pm
    Networking drinks reception

Why Attend?

  • Engage with industry peers and other stakeholders across the pricing and market access landscape
  • Discuss the commercial impact of proposals for healthcare reform
  • Explore the rise of real-world evidence in pricing models
  • Hear how innovative pricing models are being applied to support next-generation therapies

Who Attends?

FT Live has a reputation for delivering very senior, board-level audiences to attend a wide range of world-class thought-leadership events across the globe for nearly 40 years.

The FT Pharma Pricing and Value Summit will be attended by:

  • Pharmaceutical companies
  • Pharmacy benefit managers
  • Medical device manufacturers
  • Healthcare providers and insurers
  • Patient representatives and NGOs


Pharmaceutical & Medical CompaniesPrice

Standard Rate


Solution Providers & Professional Services


Standard Rate


To purchase a ticket, click here.


Founding Partner (1)

Life science companies face a rapidly evolving landscape, leading to strategic opportunities as well as challenges including the threat of disruption. Huron's life science practice is part of Huron’s continuum of healthcare offerings supporting the development and commercialization of pharmaceutical products and services.

At Huron, we work with life science companies who typically focus on:

  • Developing winning strategies and new innovative business models that go beyond individual assets and capabilities 
  • Building value and making a difference to all stakeholders throughout the healthcare continuum
  • Achieving affordable access to therapies while managing uncertainty around underlying data
  • Harnessing the power of new technologies and approaches such as digital solutions, use of real-world evidence and analytics, and companion diagnostics

Discover how Huron can help you to harness new developments and stay ahead of the curve. 

Corporate and Business Unit Strategy
Research and Development Portfolio Strategy
Market Access and Pricing
Transaction Support and Due Diligence
Asset Commercial Strategy
Organization and Innovation Development
Drug Safety and Regulatory
Digital Solutions and Technology

Lead sponsor (1)

ICON plc is a global provider of outsourced drug development and commercialisation solutions and services to pharmaceutical, biotechnology, medical device, and government and public health organisations. The company specialises in the strategic development, management and analysis of programs that support clinical development. ICON offers a full range of consulting, development and commercialisation services that help clients to accelerate the development of drugs and devices that save lives and improve quality of life.

ICON’s award-winning study execution capabilities have led to the approval of 18 of the world’s top 20 best-selling drugs.

With headquarters in Dublin, Ireland, ICON currently, operates from 97 locations in 38 countries and has approximately 13,380 employees. For further information please visit  Follow @iconplc on Twitter.

Supporting Partners (3)

When members of the Healthcare Businesswomen’s Association (HBA) come together, it’s with a shared purpose: to be a united force for change. We connect diverse groups of both women and men, across all healthcare and life science disciplines.  By taking focused action to advance our mission, we are creating a powerful movement that directly drives professional opportunity and corporate growth.  We believe that by joining forces in the relentless pursuit of gender parity, we are doing more than uniting individuals—we are strengthening the business of healthcare.

FT Health
The essential briefing for decision makers in health

FT Health is a weekly guide to the news and analysis that matters for decision makers in government, healthcare, research, industry and policy-making around the world. Leading specialists curate the best articles from the FT and across the web and make the links between the big issues. FT Health signposts important coverage on topics including infectious and non-communicable disease, public health, healthcare policy and practice, public health, research, development, drugs, vaccines and diagnostics. Straight to your inbox every Friday.

The National Pharmaceutical Council is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation. Founded in 1953 and supported by the nation’s major research-based biopharmaceutical companies, NPC focuses on research development, information dissemination, and education on the critical issues of evidence, innovation and the value of medicines for patients. Follow us on Twitter @npcnow.

Additional Resources



10 on the Park
60 Columbus Circle
10th Floor
New York 10019

United States of America

Tel: +1 212-484-6600


Nearby Accommodations

We have put together a unique Hotel Map that shows hotel deals close to the event venue. To view, click here.



Joe Hames
Sponsorship Opportunities
Financial Times
Ciaran Larkin
Content Manager
Financial Times Live
Meredith Vachon
Media Partner & Press Inquiries
Financial Times